Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > REGULATORY
REGULATORY
- Re-Pricing to Hit 23 Drugs in April; Takecab, GLP-1s, Vyndaqel/Vynmac, and More
January 19, 2022
- LDP Lawmakers Want Specific Definitions for Emergency Approval Prerequisites
January 18, 2022
- Japan Aims to Make Pfizer COVID-19 Pills Available Next Month: PM
January 18, 2022
- MHLW Panel Positive for OTC Switch for 4 Drugs Including Xyzal, Cautious on Rozerem
January 18, 2022
- Difolta Label Updated to Alleviate ADRs by Using Folinate
January 18, 2022
- Takecab Faces 2nd “Huge-Seller” Price Slash, All GLP-1 Injectables to Get Cut Too on Market Expansion
January 18, 2022
- Bayer’s CKD Drug Finerenone Up for PAFSC Review on Jan. 28
January 17, 2022
- FY2022 Medical Fee Reform Plans OK’ed by Chuikyo, No Mention of Formulary
January 17, 2022
- MHLW Presents Preventive Steps after SaMD Deferred Coverage Case: Chuikyo
January 17, 2022
- Japan Cuts Review Fees for Fertility Treatments by Half
January 14, 2022
- Pfizer’s Comirnaty Up for PAFSC Review for Ages 5-11 on Jan. 20; Actemra to Add COVID-19 Use
January 14, 2022
- MHLW to Promote Use of Generics, Biosimilars through FY2022 Medical Fee Schedule Revision: Chuikyo
January 13, 2022
- AMED to Set Up SCARDA in March to Spearhead Vaccine Development: President
January 12, 2022
- Govt to Move Up Booster Schedule for Workplace Program Too: Minister
January 12, 2022
- PM Kishida Vows to Hasten COVID-19 Vaccinations for under Age 12
January 12, 2022
- MHLW to Revise Laws to Allow Doctors to Issue Electronic Scripts
January 11, 2022
- MHLW Eyes Evaluation Indices and Guidelines to Fuel Rollout of SaMD and Cell & Gene Therapies: Official
January 11, 2022
- Govt to Submit PMD Law Amendment Bill in Ordinary Diet Session to Introduce Emergency Approval
January 7, 2022
- Rewarding Innovation Was the Primary Goal in 2022 Reform Debate: MHLW Official
January 7, 2022
- MHLW to Reshuffle Organization by Summer to Further Support Drug Development; Economic Affairs Division to Be Renamed
January 7, 2022
ページ
Japan’s health and finance ministers agreed late last year to go ahead with an “off-year” drug price revision in FY2027,…
The Japanese healthcare sector is experiencing rapid growth, demanding a highly skilled and diverse workforce. However, finding and attracting the best talent in this competitive market presents significant challenges.Enter AI. With the rise of AI-powered tools, healthcare organizations can revolutionize…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…